KR20150092738A - 에스.아우레우스 연관 질병의 치료 방법 - Google Patents

에스.아우레우스 연관 질병의 치료 방법 Download PDF

Info

Publication number
KR20150092738A
KR20150092738A KR1020157011460A KR20157011460A KR20150092738A KR 20150092738 A KR20150092738 A KR 20150092738A KR 1020157011460 A KR1020157011460 A KR 1020157011460A KR 20157011460 A KR20157011460 A KR 20157011460A KR 20150092738 A KR20150092738 A KR 20150092738A
Authority
KR
South Korea
Prior art keywords
seq
ser
nos
gly
thr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020157011460A
Other languages
English (en)
Korean (ko)
Inventor
브렛 셀만
크리스틴 트카지크
멜리사 해밀턴
레이 후아
Original Assignee
메디뮨 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 메디뮨 엘엘씨 filed Critical 메디뮨 엘엘씨
Priority to KR1020207024078A priority Critical patent/KR102272744B1/ko
Publication of KR20150092738A publication Critical patent/KR20150092738A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1271—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Micrococcaceae (F), e.g. Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1020157011460A 2012-11-06 2013-11-05 에스.아우레우스 연관 질병의 치료 방법 Ceased KR20150092738A (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020207024078A KR102272744B1 (ko) 2012-11-06 2013-11-05 에스.아우레우스 연관 질병의 치료 방법

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261723128P 2012-11-06 2012-11-06
US61/723,128 2012-11-06
PCT/US2013/068385 WO2014074470A1 (en) 2012-11-06 2013-11-05 Methods of treating s. aureus-associated diseases

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020207024078A Division KR102272744B1 (ko) 2012-11-06 2013-11-05 에스.아우레우스 연관 질병의 치료 방법

Publications (1)

Publication Number Publication Date
KR20150092738A true KR20150092738A (ko) 2015-08-13

Family

ID=50685101

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020207024078A Active KR102272744B1 (ko) 2012-11-06 2013-11-05 에스.아우레우스 연관 질병의 치료 방법
KR1020157011460A Ceased KR20150092738A (ko) 2012-11-06 2013-11-05 에스.아우레우스 연관 질병의 치료 방법
KR1020217020104A Ceased KR20210083389A (ko) 2012-11-06 2013-11-05 에스.아우레우스 연관 질병의 치료 방법

Family Applications Before (1)

Application Number Title Priority Date Filing Date
KR1020207024078A Active KR102272744B1 (ko) 2012-11-06 2013-11-05 에스.아우레우스 연관 질병의 치료 방법

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020217020104A Ceased KR20210083389A (ko) 2012-11-06 2013-11-05 에스.아우레우스 연관 질병의 치료 방법

Country Status (13)

Country Link
US (3) US9845348B2 (enExample)
EP (1) EP2928490B1 (enExample)
JP (2) JP6506172B2 (enExample)
KR (3) KR102272744B1 (enExample)
CN (2) CN104780934A (enExample)
AU (2) AU2013341421A1 (enExample)
BR (1) BR112015010126B1 (enExample)
CA (1) CA2890385C (enExample)
ES (1) ES2912267T3 (enExample)
MX (1) MX367082B (enExample)
RU (1) RU2661406C2 (enExample)
SG (2) SG10201703677VA (enExample)
WO (1) WO2014074470A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20180458T1 (hr) 2011-06-10 2018-06-29 Medimmune Limited Molekule koje vežu anti-pseudomonas psl i njihova uporaba
AU2012336028A1 (en) * 2011-11-07 2014-06-26 Medimmune, Llc Combination therapies using anti- Pseudomonas Psl and PcrV binding molecules
ES2776179T3 (es) * 2012-11-06 2020-07-29 Medimmune Llc Anticuerpos dirigidos contra determinantes de la superficie de S. aureus
RU2661406C2 (ru) * 2012-11-06 2018-07-16 МЕДИММЬЮН, ЭлЭлСи Способы лечения заболеваний, ассоциированных с s. aureus
TWI719938B (zh) 2014-06-19 2021-03-01 美商麥迪紐有限責任公司 多重細菌感染之治療
TW202311284A (zh) 2017-01-03 2023-03-16 美商再生元醫藥公司 抗金黃色葡萄球菌溶血素ａ毒素之人類抗體
WO2020023644A2 (en) 2018-07-24 2020-01-30 Medimmune, Llc Antibody directed against s. aureus clumping factor a (clfa)
CN113164602A (zh) 2018-10-09 2021-07-23 免疫医疗有限责任公司 抗金黄色葡萄球菌抗体的组合
AU2019359207A1 (en) 2018-10-09 2021-05-20 Humabs Biomed Sa Antibodies directed against Staphylococcus aureus leukotoxins
WO2020185986A1 (en) 2019-03-13 2020-09-17 Medimmune, Llc Decreasing staphylococcus aureus infections in colonized patients
CN112538112B (zh) * 2019-09-20 2023-10-27 迈威(上海)生物科技股份有限公司 抗α-溶血素的抗体及其应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2719397A1 (en) 2006-06-12 2014-04-16 GlaxoSmithKline Biologicals SA Use of alpha-toxin for treating and preventing staphylococcus infections
KR20100072228A (ko) 2007-08-31 2010-06-30 유니버시티 오브 시카고 스타필로코커스 폐 질환 및 상태에 대한 면역화와 관련된 방법 및 조성물
WO2011008939A2 (en) * 2009-07-16 2011-01-20 Medical College Of Georgia Research Institute, Inc. Porous-wall hollow glass microspheres as carriers for biomolecules
EP2284193A1 (en) 2009-08-10 2011-02-16 Kenta Biotech AG Human monoclonal antibody against S. aureus derived apha-toxin and its use in treating or preventing abscess formation
WO2012109167A1 (en) 2011-02-08 2012-08-16 Integrated Biotherapeutics, Inc. Immunogenic composition comprising alpha-hemolysin oligopeptides
US9527905B2 (en) 2011-02-08 2016-12-27 Medimmune, Llc Antibodies that specifically bind Staphylococcus aureus alpha toxin and methods of use
ES2776179T3 (es) 2012-11-06 2020-07-29 Medimmune Llc Anticuerpos dirigidos contra determinantes de la superficie de S. aureus
RU2661406C2 (ru) * 2012-11-06 2018-07-16 МЕДИММЬЮН, ЭлЭлСи Способы лечения заболеваний, ассоциированных с s. aureus
TWI719938B (zh) 2014-06-19 2021-03-01 美商麥迪紐有限責任公司 多重細菌感染之治療
WO2017075188A2 (en) 2015-10-30 2017-05-04 Medimmune, Llc Methods of using anti-alpha toxin antibody

Also Published As

Publication number Publication date
HK1215173A1 (zh) 2016-08-19
AU2013341421A1 (en) 2015-06-04
JP6926138B2 (ja) 2021-08-25
AU2018236849B2 (en) 2020-05-21
SG10201703677VA (en) 2017-06-29
US9845348B2 (en) 2017-12-19
WO2014074470A1 (en) 2014-05-15
AU2018236849A1 (en) 2018-10-18
BR112015010126A2 (enExample) 2017-08-22
ES2912267T3 (es) 2022-05-25
EP2928490A4 (en) 2016-11-02
SG11201503231YA (en) 2015-05-28
KR20200102533A (ko) 2020-08-31
JP2019142888A (ja) 2019-08-29
EP2928490A1 (en) 2015-10-14
MX367082B (es) 2019-08-05
MX2015005481A (es) 2016-01-14
US20200109191A1 (en) 2020-04-09
US20160257733A1 (en) 2016-09-08
US10759849B2 (en) 2020-09-01
RU2015121617A (ru) 2016-12-27
EP2928490B1 (en) 2022-03-30
JP2015536951A (ja) 2015-12-24
CN104780934A (zh) 2015-07-15
CA2890385C (en) 2022-07-12
CA2890385A1 (en) 2014-05-15
CN112316135A (zh) 2021-02-05
KR20210083389A (ko) 2021-07-06
KR102272744B1 (ko) 2021-07-06
US10457724B2 (en) 2019-10-29
US20190002540A1 (en) 2019-01-03
JP6506172B2 (ja) 2019-04-24
RU2661406C2 (ru) 2018-07-16
BR112015010126B1 (pt) 2022-11-01

Similar Documents

Publication Publication Date Title
JP6926138B2 (ja) 黄色ブドウ球菌（Ｓ．ａｕｒｅｕｓ）関連性疾患を治療する方法
KR102288394B1 (ko) 스타필로코커스 아우레우스 표면 결정인자에 대한 항체
KR101993839B1 (ko) 스타필로코커스 아우레우스 알파 독소에 특이적으로 결합하는 항체 및 이의 사용 방법
CN102770453B (zh) 抗flt3抗体及其使用方法
US20150044168A1 (en) Treatment of Multiple Sclerosis With Anti-CD19 Antibody
HK1215173B (en) Methods of treating s. aureus-associated diseases
US20240109961A1 (en) Treatment of chronic prurigo
WO2025250726A1 (en) Anti-kit antibody dosing and methods
TW202511292A (zh) 用於治療ＮＳＣＬＣ及ｃＨＬ之ＰＤ－１／ＴＩＭ－３結合蛋白
TW202506180A (zh) 用於癌症治療之pd-1/tigit結合蛋白
CN117120089A (zh) 慢性痒疹的治疗
RU2808018C2 (ru) Антитела к поверхностным детерминантам s. aureus

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20150430

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20181031

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20191220

Patent event code: PE09021S01D

E90F Notification of reason for final refusal
PE0902 Notice of grounds for rejection

Comment text: Final Notice of Reason for Refusal

Patent event date: 20200417

Patent event code: PE09021S02D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20200723

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20200417

Comment text: Final Notice of Reason for Refusal

Patent event code: PE06011S02I

Patent event date: 20191220

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20200820